Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iclaprim - Motif Bio

Drug Profile

Iclaprim - Motif Bio

Alternative Names: AR-100; MTF-100; Ro-48-2622

Latest Information Update: 08 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Arpida; Evolva Holding SA; Motif Bio; Otto von Guericke University Magdeburg
  • Class Amines; Anti-infectives; Antibacterials; Antiprotozoals; Pyrimidines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methicillin-resistant Staphylococcus aureus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Skin and soft tissue infections
  • Phase II Nosocomial pneumonia
  • Preclinical Methicillin-resistant Staphylococcus aureus infections; Staphylococcal infections; Toxoplasmosis
  • No development reported Nosocomial infections
  • Discontinued Chlamydial infections; Gonorrhoea

Most Recent Events

  • 08 Nov 2019 Motif Bio plans a preclinical study for wound infection
  • 31 Oct 2019 Motif Bio entered into research agreement with Walter Reed Army Institute of Research to conduct preclinical testing
  • 10 Oct 2019 Iclaprim is available for commercial licensing in World as of 10 Oct 2019. www.motifbio.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top